[1]
|
Okabayashi, T., Shima, Y., Sumiyoshi, T., et al. (2013) Diagnosis and Management of Insulinoma. World Journal of Gastroenterology, 19, 829-837. https://doi.org/10.3748/wjg.v19.i6.829
|
[2]
|
Service, F.J., McMahon, M.M., O’Brien, P.C. and Ballard, D.J. (1991) Functioning Insulinoma—Incidence, Recurrence, and Long-Term Survival of Pa-tients: A 60-Year Study. Mayo Clinic Proceedings, 66, 711-719.
https://doi.org/10.1016/S0025-6196(12)62083-7
|
[3]
|
Wild, A., Langer, P., Ramaswamy, A., Chaloupka, B. and Bartsch, D.K. (2001) A Novel Insulinoma Tumor Suppressor Gene Locus on Chromosome 22q with Potential Prognos-tic Implications. The Journal of Clinical Endocrinology & Metabolism, 86, 5782-5787. https://doi.org/10.1210/jcem.86.12.8089
|
[4]
|
Jiang, W.J., Liu, T.H., Chen, J., Gao, J., Wu, S.F. and Chen, Y.J. (2004) Frequent Loss of Heterozygosity at MEN-1 gene and Chromosome 22q in Insulinomas and Its Significance. Chi-nese Medical Journal, 84, 1705-1709.
|
[5]
|
蒋卫君, 刘彤华, 陈杰, 等. 胰岛素瘤频发MEN-1抑癌基因及22q的杂合缺失及其意义[J]. 中华医学杂志, 2004(20): 37-41.
|
[6]
|
Jonkers, Y.M., Claessen, S.M., Feuth, T., et al. (2006) Novel Candidate Tumour Suppressor Gene Loci on Chromosomes 11q23-24 and 22q13 Involved in Human Insulinoma Tumourigenesis. The Journal of Pathology, 210, 450-458.
https://doi.org/10.1002/path.2072
|
[7]
|
Li, J.W.Y., Hua, X., Reidy-Lagunes, D. and Untch, B.R. (2018) MENIN Loss as a Tissue-Specific Driver of Tumorigenesis. Molecular and Cellular Endocrinology, 469, 98-106. https://doi.org/10.1016/j.mce.2017.09.032
|
[8]
|
Bertolino, P., Tong, W.M., Herrera, P.L., Casse, H., Zhang, C.X. and Wang, Z.Q. (2003) Pancreatic Beta-Cell-Specific Ablation of the Multiple Endocrine Neoplasia Type 1 (MEN1) Gene Causes Full Penetrance of Insulinoma Development in Mice. Cancer Research, 63, 4836-4841.
|
[9]
|
段佳悦. 通过外显子组基因测序发现2个MEN1基因突变可导致散发性胰岛素细胞瘤[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2018.
|
[10]
|
Dejeux, E., Olaso, R., Dousset, B., et al. (2009) Hypermethylation of the IGF2 Differentially Methylated Region 2 Is a Specific Event in Insulinomas Leading to Loss-of-Imprinting and Overexpression. Endo-crine-Related Cancer, 16, 939-952. https://doi.org/10.1677/ERC-08-0331
|
[11]
|
李旭. 胰岛素瘤定性诊断及IGF2在其发病中的作用研究[D]: [硕士学位论文]. 上海: 上海交通大学, 2017.
|
[12]
|
Cao, Y., Gao, Z., Li, L., et al. (2013) Whole Exome Sequencing of Insulinoma Reveals Recurrent T372R Mutations in YY1. Nature Communications, 4, Arti-cle No. 2810. https://doi.org/10.1038/ncomms3810
|
[13]
|
Hong, X., Qiao, S., Li, F., et al. (2020) Whole-Genome Sequencing Reveals Distinct Genetic Bases for Insulinomas and Non-Functional Pancreatic Neuroendocrine Tumours: Leading to a New Classification System. Gut, 69, 877-887.
https://doi.org/10.1136/gutjnl-2018-317233
|
[14]
|
Tuttle, R.L., Gill, N.S., Pugh, W., et al. (2001) Regulation of Pancreatic Beta-Cell Growth and Survival by the Serine/Threonine Protein Kinase Akt1/PKBalpha. Nature Medicine, 7, 1133-1137. https://doi.org/10.1038/nm1001-1133
|
[15]
|
Zhou, W., Gong, L., Li, X., et al. (2018) Screening Key Candidate Genes and Pathways Involved in Insulinoma by Microarray Analysis. Medicine (Baltimore), 97, e10826. https://doi.org/10.1097/MD.0000000000010826
|
[16]
|
Yin, Y.J., Salah, Z., Maoz, M., et al. (2003) Oncogenic Transformation Induces Tumor Angiogenesis: A Role for PAR1 Activation. FASEB Journal, 17, 163-174. https://doi.org/10.1096/fj.02-0316com
|
[17]
|
Wojtukiewicz, M.Z., Hempel, D., Sierko, E., Tucker, S.C. and Honn, K.V. (2019) Endothelial Protein C Receptor (EPCR), Protease Activated Receptor-1 (PAR-1) and Their Interplay in Cancer Growth and Metastatic Dissemination. Cancers (Basel), 11, Article No. 51. https://doi.org/10.3390/cancers11010051
|
[18]
|
Kreutter, G., Kassem, M., El Habhab, A., et al. (2017) Endothelial Microparticles Released by Activated Protein C Protect Beta Cells through EPCR/PAR1 and Annexin A1/FPR2 Path-ways in Islets. Journal of Cellular and Molecular Medicine, 21, 2759-2772. https://doi.org/10.1111/jcmm.13191
|
[19]
|
Yamanaka, Y., Friess, H., Büchler, M., Beger, H.G., Gold, L.I. and Korc, M. (1993) Synthesis and Expression of Transforming Growth Factor beta-1, beta-2, and beta-3 in the Endocrine and Ex-ocrine Pancreas. Diabetes, 42, 746-756.
https://doi.org/10.2337/diab.42.5.746
|
[20]
|
Heidegger, I., Fotakis, G., Offermann, A., et al. (2022) Comprehensive Characterization of the Prostate Tumor Microenvironment Identifies CXCR4/CXCL12 Crosstalk as a Novel Antiangio-genic Therapeutic Target in Prostate Cancer. Molecular Cancer, 21, Article No. 132. https://doi.org/10.1186/s12943-022-01597-7
|
[21]
|
Daniel, S.K., Seo, Y.D. and Pillarisetty, V.G. (2020) The CXCL12-CXCR4/CXCR7 Axis as a Mechanism of Immune Resistance in Gastrointestinal Malignancies. Seminars in Cancer Biology, 65, 176-188.
https://doi.org/10.1016/j.semcancer.2019.12.007
|
[22]
|
Luo, N., Chen, D.D., Liu, L., Li, L. and Cheng, Z.P. (2019) CXCL12 Promotes Human Ovarian Cancer Cell Invasion through Suppressing ARHGAP10 Expression. Biochemical and Biophysical Research Communications, 518, 416-422.
https://doi.org/10.1016/j.bbrc.2019.07.098
|
[23]
|
Qin, Y., Wang, F., Ni, H., et al. (2021) Cancer-Associated Fibro-blasts in Gastric Cancer Affect Malignant Progression via the CXCL12-CXCR4 Axis. Journal of Cancer, 12, 3011-3023. https://doi.org/10.7150/jca.49707
|
[24]
|
Ilhan, A., Nabokikh, A., Maj, M., et al. (2009) CXCL12/SDF-1 Over-Expression in Human Insulinomas and Its Biological Relevance. Molecular and Cellular Endocrinology, 298, 1-10. https://doi.org/10.1016/j.mce.2008.10.015
|
[25]
|
Molkentin, J.D. (2000) The Zinc Finger-Containing Transcription Factors GATA-4, -5, and -6. Ubiquitously Expressed Regulators of Tissue-Specific Gene Expression. Journal of Bio-logical Chemistry, 275, 38949-38952.
https://doi.org/10.1074/jbc.R000029200
|
[26]
|
魏美林. Gata6在胰岛素瘤中的作用及机制研究[D]: [硕士学位论文]. 上海: 上海交通大学, 2015.
|
[27]
|
Gu, M., Guan, J., Zhao, L., Ni, K., Li, X. and Han, Z. (2013) Correlation of ECM1 Expression Level with the Pathogenesis and Metastasis of Laryngeal Carcinoma. International Journal of Clinical and Experimental Pathology, 6, 1132-1137.
|
[28]
|
Chen, H., Jia, W.D., Li, J.S., et al. (2011) Extracellular Matrix Protein 1, a Novel Prognostic Factor, Is Associated with Metastatic Potential of Hepatocellular Carcinoma. Medical Oncology, 28, S318-S325.
https://doi.org/10.1007/s12032-010-9763-1
|
[29]
|
Zhang, Y. and Weinberg, R.A. (2018) Epithelial-to-Mesenchymal Transition in Cancer: Complexity and Opportunities. Frontiers in Medicine, 12, 361-373. https://doi.org/10.1007/s11684-018-0656-6
|
[30]
|
Thompson, E.W., Newgreen, D.F. and Tarin, D. (2005) Carcino-ma Invasion and Metastasis: A Role for Epithelial-Mesenchymal Transition? Cancer Research, 65, 5991-5995. https://doi.org/10.1158/0008-5472.CAN-05-0616
|
[31]
|
Escot, S., Willnow, D., Naumann, H., Di Francescantonio, S. and Spagnoli, F.M. (2018) Robo Signalling Controls Pancreatic Progenitor Identity by Regulating Tead Transcription Factors. Nature Communications, 9, Article No. 5082.
https://doi.org/10.1038/s41467-018-07474-6
|
[32]
|
Chen, H.T., Liu, H., Mao, M.J., et al. (2019) Crosstalk between Autophagy and Epithelial-Mesenchymal Transition and Its Application in Cancer Therapy. Molecular Cancer, 18, 101. https://doi.org/10.1186/s12943-019-1030-2
|
[33]
|
Michael, I.P., Saghafinia, S. and Hanahan, D. (2019) A Set of microRNAs Coordinately Controls Tumorigenesis, Invasion, and Metastasis. Proceedings of the National Academy of Sciences of the United States of America, 116, 24184-24195.
https://doi.org/10.1073/pnas.1913307116
|
[34]
|
Wei, J., Liu, X., Wu, J., et al. (2016) Diagnosis and Surgical Man-agement of Insulinomas in 33 Consecutive Patients at a Single Institution. Langenbeck’s Archives of Surgery, 401, 1019-1025. https://doi.org/10.1007/s00423-016-1496-y
|
[35]
|
Garcia-Carbonero, R., Sorbye, H., Baudin, E., et al. (2016) ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendo-crine Carcinomas. Neuroendocrinology, 103, 186-194.
https://doi.org/10.1159/000443172
|
[36]
|
Hirshberg, B., Livi, A., Bartlett, D.L., et al. (2000) Forty-Eight-Hour Fast: The Diagnostic Test for Insulinoma. The Journal of Clinical Endocrinology & Metabolism, 85, 3222-3226. https://doi.org/10.1210/jcem.85.9.6807
|
[37]
|
Mehrabi, A., Fischer, L., Hafezi, M., et al. (2014) A Systematic Re-view of Localization, Surgical Treatment Options, and Outcome of Insulinoma. Pancreas, 43, 675-686. https://doi.org/10.1097/MPA.0000000000000110
|
[38]
|
Antwi, K., Fani, M., Heye, T., et al. (2018) Comparison of Glucagon-Like Peptide-1 Receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the Localisation of Occult Insulino-mas: Evaluation of Diagnostic Accuracy in a Prospective Crossover Imaging Study. European Journal of Nuclear Medi-cine and Molecular Imaging, 45, 2318-2327.
https://doi.org/10.1007/s00259-018-4101-5
|
[39]
|
ASGE Standards of Practice Committee, Eloubeidi, M.A., Decker, G.A., et al. (2016) The Role of Endoscopy in the Evaluation and Management of Patients with Solid Pancreatic Neoplasia. Gastrointestinal Endoscopy, 83, 17-28.
https://doi.org/10.1016/j.gie.2015.09.009
|
[40]
|
Sharma, P., Arora, S., Karunanithi, S., et al. (2016) Somatostatin Receptor Based PET/CT Imaging with 68Ga- DOTA-Nal3-Octreotide for Localization of Clinically and Biochemically Suspected Insulinoma. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 60, 69-76.
|
[41]
|
罗亚平, 潘青青, 霍力, 李方. 胰高血糖素样肽-1受体显像定位诊断胰岛素瘤的研究进展[J]. 中国科学: 生命科学, 2021, 51(8): 1072-1084.
|
[42]
|
Velikyan, I. and Eriksson, O. (2020) Advances in GLP-1 Receptor Targeting Radiolabeled Agent Development and Prospective of Theranostics. Theranostics, 10, 437-461. https://doi.org/10.7150/thno.38366
|
[43]
|
Wild, D., Christ, E., Caplin, M.E., et al. (2011) Glucagon-Like Peptide-1 versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant Insulinomas. Journal of Nuclear Medi-cine, 52, 1073-1078.
https://doi.org/10.2967/jnumed.110.085142
|
[44]
|
Ito, T., Igarashi, H. and Jensen, R.T. (2012) Pancreatic Neuroen-docrine Tumors: Clinical Features, Diagnosis and Medical Treatment: Advances. Best Practice & Research Clinical Gas-troenterology, 26, 737-753.
https://doi.org/10.1016/j.bpg.2012.12.003
|
[45]
|
韩序, 楼文晖. 胰腺神经内分泌肿瘤的外科决策[J]. 肝胆外科杂志, 2021, 29(3): 168-170.
|
[46]
|
de Herder, W.W., Niederle, B., Scoazec, J.Y., et al. (2006) Well-Differentiated Pan-creatic Tumor/Carcinoma: Insulinoma. Neuroendocrinology, 84, 183-188. https://doi.org/10.1159/000098010
|
[47]
|
Cuccurullo, V., Di Stasio, G.D. and Mansi, L. (2019) Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours. Current Radiopharmaceuticals, 12, 98-106.
https://doi.org/10.2174/1874471012666190206094555
|
[48]
|
Burr, I.M., Marliss, E.B., Stauffacher, W. and Renold, A.E. (1971) Diazoxide Effects on Biphasic Insulin Release: “Adrenergic” Suppression and Enhancement in the Perifused Rat Pancreas. Journal of Clinical Investigation, 50, 1444-1450. https://doi.org/10.1172/JCI106628
|
[49]
|
Niitsu, Y., Minami, I., Izumiyama, H., et al. (2019) Clinical Outcomes of 20 Japanese Patients with Insulinoma Treated with Di-azoxide. Endocrine Journal, 66, 149-155. https://doi.org/10.1507/endocrj.EJ18-0353
|
[50]
|
Healy, M.L., Dawson, S.J., Murray, R.M., Zalcberg, J. and Jefford, M. (2007) Severe Hypoglycaemia after Long-Acting Octreotide in a Patient with an Unrecognized Malignant Insulinoma. Internal Medicine Journal, 37, 406-409.
https://doi.org/10.1111/j.1445-5994.2007.01371.x
|
[51]
|
Mathur, A., Gorden, P. and Libutti, S.K. (2009) Insulinoma. Surgical Clinics of North America, 89, 1105-1121.
https://doi.org/10.1016/j.suc.2009.06.009
|
[52]
|
Yamaoka, K., Nagashima, S., Okada, N., et al. (2021) A Case of Insulinoma with Hypoglycemia That Was Better Managed with Lanreotide than Octreotide. Clinical Case Reports, 9, e04118. https://doi.org/10.1002/ccr3.4118
|
[53]
|
吴文铭, 陈洁, 白春梅, 等. 中国胰腺神经内分泌肿瘤诊疗指南(2020) [J]. 协和医学杂志, 2021, 12(4): 460-480.
|
[54]
|
Cryer, P.E., Axelrod, L., Grossman, A.B., et al. (2009) Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 94, 709-728.
https://doi.org/10.1210/jc.2008-1410
|
[55]
|
Habibollahi, P., Bai, H.X., Sanampudi, S., Soulen, M.C. and Dagli, M. (2020) Effectiveness of Liver-Directed Therapy for the Management of Intractable Hypoglycemia in Metastatic Insulino-ma. Pancreas, 49, 763-767.
https://doi.org/10.1097/MPA.0000000000001569
|
[56]
|
Rougier, P. and Mitry, E. (2000) Chemotherapy in the Treatment of Neuroendocrine Malignant Tumors. Digestion, 62, 73-78. https://doi.org/10.1159/000051859
|
[57]
|
Broder, L.E. and Carter, S.K. (1973) Pancreatic Islet Cell Carcinoma. II. Results of Therapy with Streptozotocin in 52 Patients. Annals of Internal Medicine, 79, 108-118. https://doi.org/10.7326/0003-4819-79-1-108
|
[58]
|
Cives, M. and Strosberg, J.R. (2018) Gastroenteropancreatic Neuroendocrine Tumors. CA: A Cancer Journal for Clinicians, 68, 471-487. https://doi.org/10.3322/caac.21493
|
[59]
|
Yao, J.C., Shah, M.H., Ito, T., et al. (2011) Everolimus for Advanced Pancreatic Neuroendocrine Tumors. The New England Journal of Medicine, 364, 514-523. https://doi.org/10.1056/NEJMoa1009290
|
[60]
|
Brown, E., Watkin, D., Evans, J., Yip, V. and Cuthbertson, D.J. (2018) Multidisciplinary Management of Refractory Insulinomas. Clinical Endocrinology (Oxford), 88, 615-624. https://doi.org/10.1111/cen.13528
|
[61]
|
Peltola, E., Hannula, P., Huhtala, H., et al. (2021) Long-Term Morbidity and Mortality in Patients Diagnosed with an Insulinoma. European Journal of Endocrinology, 185, 577-586. https://doi.org/10.1530/EJE-21-0230
|